← Eichor
Condition: Relapsed Refractory Hematopoietic Malignancies Acute Myeloid Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Relapsed Refractory Hematopoietic Malignancies Acute Myeloid

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients
NA · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07500753Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
Phase 1/Phase 2 · 1 location(s) · Children's Hospital of Philadelphia · NCT06839456CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial
EARLY_Phase 1 · 1 location(s) · Institute of Hematology and Blood Transfusion, Czech Republi · NCT06765876HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Ste
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT03326921Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen
Phase 2 · 1 location(s) · St. Petersburg State Pavlov Medical University · NCT06532084Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment o
Phase 1 · 2 location(s) · Catherine Bollard · NCT02203903Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell
Phase 2 · 1 location(s) · Federal Research Institute of Pediatric Hematology, Oncology · NCT07256210IS-free Treg HaploHCT
Phase 1 · 1 location(s) · Dana-Farber Cancer Institute · NCT04678401Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT06928662Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transpla
Phase 2 · 1 location(s) · Peking University People's Hospital · NCT06869265211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Le
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT03670966Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumor
Phase 1 · 1 location(s) · University of Wisconsin, Madison · NCT02508038Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Phase N/A · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137643A Single-arm, Prospective Study of TBI + BUMEL As a Conditioning Regimen for Salvage HSCT in Patients with R/R AML
NA · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06879847Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT
Phase 1/Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT07591649CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relap
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT04375631
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.